CorMedix Inc. · NASDAQ:CRMD
CorMedix — Investor Presentation (September 2020)
21 slides from CorMedix's investor presentation, Sep 1, 2020

Slide 1: Defencath: A potentially new standard-of-care in prevention of catheter related blood stream infections
DefencathTM: A potentially new standard-of-care in the prevention of catheter related blood stream infections CORMEDIX

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Th

Slide 3: Defencath is a Novel Product Targeting Substantial Market Opportunities
DefencathTM is a Novel Product Targeting Substantial Market Opportunities • Defencath is a novel catheter lock solution with the potential to change the standard of care in several large markets – no current Novel Product Addressing a pharmacologic agent approved to prevent infections associated wit

Slide 4: CorMedix Senior Management Team
CorMedix Senior Management Team Khoso Baluch Chief Executive Officer EVP and Chief Financial Matt David, MD Officer Phoebe Mounts, PhD, JD EVP and General Counsel Paul Chew, MD Chief Medical Officer Jack Armstrong EVP Technical Operations EVP & Head of Clinical Elizabeth Masson Hurlburt Operations C

Slide 5: Targeting a Substantial Commercial Market Opportunity
Targeting a Substantial Commercial Market Opportunity • No pharmacologic agents approved in the U.S. for the prevention of CRBSI in central venous catheters • Total annual cost in U.S. for treating all CRBSI and their complications up to $2.7B • Multiple organizations are focused on reducing CRBSIs

Slide 6: Defencath/Neutrolin is an Anti-Bacterial and Anti-Fungal Catheter Lock Solution
DefencathTM/Neutrolin® is an Anti-Bacterial and Anti-Fungal Catheter Lock Solution Designed to Prevent CRBSIs and Clotting • Used to fill catheter lumens when they are not in use to prevent microbial growth and clotting DEFENCATH / NEUTROLIN PROPRIETARY FORMULATION NEUTROLIN/DEFENCATH REGULATORY STA

Slide 7: LOCK-IT-100 – Pivotal Clinical Trial Design
LOCK-IT-100 – Pivotal Clinical Trial Design • Phase 3, multicenter, double-blind, randomized (1:1), active control (heparin) • Event-driven: 56 CRBSI events required to complete the study; 28 CRBSI events at Interim Analysis met pre-specified DESIGN efficacy endpoint without safety concerns and Data

Slide 8: Phase 3 LOCK-IT-100 – Topline Results
Phase 3 LOCK-IT-100 – Topline Results Primary endpoint met – highly statistically significant efficacy Secondary safety endpoints met - no statistically significant differences between Defencath (D) & Heparin (H) control arm for loss of catheter patency and catheter removal Interim Analysis Full

Slide 9: Phase 3 LOCK-IT-100 – Conclusions
Phase 3 LOCK-IT-100 – Conclusions LOCK-IT-100, a landmark study, showed that in ESRD subjects with hemodialysis via a 01 central venous catheter, Defencath catheter lock solution significantly reduced catheter- related bloodstream infections by 71% (p=0.0006) in 795 patients (9 D, 32 H). Compared to

Slide 10: Defencath Regulatory Status
Defencath Regulatory Status • FDA granted rolling submission and review of Defencath New Drug Application • Ongoing dialogue with FDA on submitted modules • FDA accepted submitted NDA for filing • FDA had 60-day period to review for completeness and to make filing decision • Priority review granted

Slide 11: Defencath Pricing Will be Supported by its Clinical and Economic Benefits
Defencath Pricing Will be Supported by its Clinical Benefit and Economic Benefits to the Healthcare System Several factors currently being assessed to derive pricing include: 1 In the US, will be the first approved antimicrobial catheter lock solution 2 Facilities and patients involved in at-risk ar

Slide 12: Medicare (CMS) Accounts for ~90% of ESRD Reimbursement
Medicare (CMS) Accounts for ~90% of ESRD Reimbursement and is Very Focused on Quality of Care ESRD PPS has quality measures as part of its Payer Mix for Dialysis Coverage reimbursement More Choice Patients methodology 19% Medicare coverage kicks in Quality of Care Measures Medicare Advantage ~1% • E

Slide 13: Defencath Reimbursement Opportunity Through TDAPA
Defencath Reimbursement Opportunity Through TDAPA Under new regulations effective January 2020, New Chemical Entities (NCEs) are eligible for CMS reimbursement outside the bundle under the TDAPA* program • The intent of the TDAPA is to facilitate beneficiary access to certain new renal dialysis drug

Slide 14: CorMedix Believes Defencath is Eligible for and Will Obtain TDAPA
CorMedix Believes Defencath is Eligible for and Will Obtain TDAPA Highlights of Rationale to Support TDAPA FDA Fast-Track Designation Unmet Medical Need FDA Designated as Qualified Infectious Disease Product (QIDP) No standard of care has been established to prevent CRBSIs in hemodialysis pati

Slide 15: Commercial Execution Can Be Accomplished With a Highly Focused Organization
Commercial Execution Can Be Accomplished With a Highly Focused Organization Map of the standardized incidence rate of ESRD, by Health An initial commercial organization of ~50 people can provide Service Area, in the U.S. population, 2012 - present adequate coverage for launch into hemodialysis: • Th

Slide 16: Label Expansion Into Other CVC Areas Provides Opportunities
Label Expansion Into Other CVC Areas Provides Opportunities; Oncology has Compelling Dynamics • There are multiple natural extension opportunities for Defencath beyond hemodialysis catheters Share with Estimated Patients Market: # of CLS Patient Population Central Venous (2019) per year 2025 • Among

Slide 17: Manufacturing Overview: Supply Chain Substantially Completed
Manufacturing Overview: Supply Chain Substantially Completed; Launch Quantities in Production • Successfully concluded technical transfer and validation of the drug product manufacturing process, which has enabled production at 2 different manufacturing locations • Company has DMF for taurolidine; p

Slide 18: Marketing Exclusivity and Intellectual Property
Marketing Exclusivity and Intellectual Property MARKET EXCLUSIVITY • Upon approval, 10.5 years of potential market exclusivity • Designated an Investigational New Drug by FDA • New Chemical Entity (NCE) Status – 5 years of exclusivity • Designated as Qualified Infectious Disease Product (QIDP) – add

Slide 19: Financial Highlights
Financial Highlights KEY STATISTICS • Exchange: NYSE American (CRMD) • Common Stock: 31.2 million shares as of 8/6/2020 • Market cap: ~$150 million BALANCE SHEET • Cash: $22.4 million as of 6/30/2020 • Pro forma Cash*: $43.9 million as of 6/30/2020 • Debt: None * Inclusive of net proceeds from July

Slide 20: CorMedix Key Highlights
CorMedix Key Highlights Defencath is a Novel Anticipating Potential Product Addressing a FDA Approval in Lead Potential for 10.5 Years of Significant Unmet Indication of Market Exclusivity Medical Need Hemodialysis Substantial Market Data Demonstrate Opportunities in Senior Leadership with Effective

Slide 21: CorMedix
venous catheter a
Source: Internet Archive copy of cormedix.com
More decks from CorMedix Inc.
Merger or Acquisition (November 2026)7 slides · Nov 10, 2026
Merger or Acquisition (November 2026)7 slides · Nov 9, 2026
Technical Presentation (October 2026)16 slides · October 2026
CorMedix Therapeutics — Investor Presentation (September 2026)25 slides · September 2026
CorMedix Therapeutics — Investor Presentation (May 2026)24 slides · May 2026
Investor Presentation (March 2026)23 slides · Mar 6, 2026